Home » News » Awards & Advancement » KYTHERA raises $37.4 million in Series D financing

KYTHERA raises $37.4 million in Series D financing

Monday, September 19, 2011

KYTHERA Biopharmaceuticals has closed a $37.4M Series D financing round. The round featured significant new investments as well as participation from all existing institutional investors. Proceeds from this financing are slated to be used for conducting US phase III trials for KYTHERA’s lead product, ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.

KYTHERA’s investors include Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, JAFCO, Partner Funds management (PFM), INVUS Financial Advisors, BBT Capital Management/Apothecary Capital, and Altitude Life Science Ventures. Also joining the syndicate were Foley Ventures and Latham and Watkins. KYTHERA has now raised more than $108M in four rounds of private financing.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!